Anti-dumping probe on Penicillin G tests the PLI-backed API revival
India has opened an anti-dumping investigation into Penicillin G imports from China after the country's only producer — revived under the production linked incentive scheme on a ₹2,500 crore plant — said import prices forced it to cut its own and left it short of planned output.
What happened
The Directorate General of Trade Remedies has initiated an anti-dumping investigation into imports of Penicillin G and its salts from China, after domestic manufacturer Lyfius Pharma alleged the imports were causing material retardation to the industry and sought anti-dumping duties. Lyfius, an Aurobindo Pharma subsidiary, said it is the sole eligible producer of the product in India with no other domestic manufacturers, and that it has not achieved production and sales as expected and was forced to reduce prices to match the landed price of imports. The DGTR said there is sufficient prima facie evidence of dumping and accepted 2025-26 as the period of investigation.
Context
Lyfius began manufacturing Penicillin G more than two years ago under the government's production linked incentive scheme, reviving output of the beta-lactam antibiotic in India after about three decades. India manufactured Penicillin G until the late 1980s, but after globalisation a sustained influx of imports closed every domestic plant producing it. Prime Minister Narendra Modi inaugurated the company's 15,000 tonnes facility at Kakinada in Andhra Pradesh in October 2024, which Aurobindo described as a strategic ₹2,500 crore investment under the pharmaceutical PLI scheme.
Why it matters
This is the sequencing problem in import-substituting industrial policy, arriving on schedule. A subsidy can pay for a plant, but it cannot by itself make that plant's output competitive against an incumbent exporter with three decades of accumulated scale. The legal ground Lyfius has pleaded is the giveaway: "material retardation" to an industry, which is the category used where an industry is being established rather than one already injured, and it exists precisely for infant industries. The product matters beyond the firm. Penicillin G is a key starting material and active pharmaceutical ingredient for medicines treating bacterial infections including pneumonia, dental infections, diphtheria and meningitis, so dependence on a single foreign source for it is a health-security exposure as much as a trade one. The investigation covers Penicillin G in all forms, grades, strengths and concentrations and its salt forms, whether or not conforming to pharmacopoeial standards, in both solid and liquid forms — a deliberately wide scope that makes the remedy hard to route around by reformulating.
Impact for India
- Lyfius Pharma: the sole eligible domestic producer, which says it could not reach planned production and sales and cut prices to match landed import prices.
- The PLI scheme's logic: a ₹2,500 crore plant with 15,000 tonnes of capacity needs the price it was modelled on, which is what the duty would restore.
- Antibiotic supply security: Penicillin G is a key starting material and active pharmaceutical ingredient for treatments of pneumonia, diphtheria, meningitis and dental infections, so single-source import dependence is a health exposure.
- Formulators and downstream buyers: a duty would raise the input cost of the antibiotics made from it, since there is only one domestic supplier to switch to.
- Scope of the remedy: all forms, grades, strengths, concentrations and salt forms, solid and liquid, whether or not pharmacopoeial — wide enough to limit circumvention.
Key data
Concepts
Theory lens
The infant industry argument — a domestic producer may be unable to compete initially despite being viable at scale, because an established rival has already descended its learning and scale curve. Temporary protection is justified only if the industry would become competitive, and this case sets out the test in real terms: a ₹2,500 crore plant with 15,000 tonnes of capacity, protected on a material-retardation ground, with the question being whether it reaches competitive cost before the protection becomes permanent.
Historical parallel
India made Penicillin G domestically until the late 1980s, and then lost the capability entirely — after globalisation, a sustained influx of imports led to the closure of every plant producing the antibiotic in the country. That episode is the reason the current plant exists under a subsidy scheme and the reason its producer is now asking for a duty: the first round of exposure ended in exit rather than adaptation.
Stakeholders
Practice Question — from the story
With reference to the anti-dumping investigation into Penicillin G, consider the following statements:
- The complainant says it is the sole eligible domestic producer, having revived Indian output of the antibiotic after about three decades under the production linked incentive scheme.
- The complaint is made on the ground of material retardation, which applies where dumped imports prevent an industry from becoming established.
Which of the statements given above is/are correct?
Reveal answer & explanation
Answer: Both 1 and 2
- Statement 1: Correct — Lyfius Pharma stated it is the sole eligible producer with no other domestic manufacturers, having begun making Penicillin G more than two years ago under the PLI scheme after India stopped producing it following the late 1980s.
- Statement 2: Correct — material retardation is the ground pleaded, and it fits a producer that restarted output recently rather than one with an established position being injured.
Therefore, the correct answer is Both 1 and 2.
Concept check — test your understanding
What does the infant industry argument require before temporary protection is justified?
Reveal answer & explanation
Answer: B
- The case for shielding a new entrant rests on a temporary cost disadvantage that falls away with scale and learning. If the industry would never become competitive, protection becomes a permanent transfer from buyers rather than an investment in capability.
- Option A invokes an employment rationale which is politically common but is a different argument from the infant industry case.
- Option C matters for how the burden of a duty falls — and Penicillin G is indeed essential — but necessity does not establish future competitiveness.
- Option D describes the ground for a countervailing duty, which is an adjacent but distinct remedy from anti-dumping.